Oncolytics Biotech Inc. (ONCY) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 8 Buy, 2 Hold.
Analysts estimate Earnings Per Share (EPS) of $-0.42 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.41 vs est $-0.42 (beat +2.1%). 2025: actual $-0.30 vs est $-0.34 (beat +12.5%). Analyst accuracy: 92%.
ONCY Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Oncolytics Biotech Inc. in the past 3 months
EPS Estimates — ONCY
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.41
vs Est –$0.42
▲ 2.2% off
2025
Actual –$0.30
vs Est –$0.34
▲ 14.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ONCY
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
